AFFF Firefighting Foam lawsuit update

Verified snapshot

The facts that anchor this dossier

The AFFF docket contains different kinds of claims under one procedural roof. This guide separates personal-injury bellwethers from public-water settlements and explains the developing PFAS science without turning association into individual causation.

Federal proceeding

MDL 2873

Coordinated in the District of South Carolina before Judge Richard M. Gergel.

Pending actions

15,244

JPML count as of July 1, 2026; 19,819 historical actions. The docket includes more than one claim category.

Personal-injury status

Bellwether development continues

A March 17, 2026 order advanced selected Group B cases toward expert discovery and set proposals due July 20, 2026.

Claim categories

Personal injury, water systems, property and medical monitoring

A settlement for a public water system is not a personal-injury settlement.

Health evidence

Associations vary by specific PFAS

ATSDR lists associations for certain PFAS and outcomes while emphasizing exposure, individual factors and study limitations.

Documented chronology

How the litigation reached this point

One MDL, several very different disputes

AFFF is shorthand for aqueous film-forming foam, a product used to suppress flammable-liquid fires at places such as military installations, airports, refineries and training facilities. The South Carolina court explains that plaintiffs generally allege PFOA- or PFOS-containing foams contaminated groundwater and caused personal injury, a need for medical monitoring, property damage or economic loss. That procedural umbrella is broad; it should not be mistaken for a single claim form or a single settlement.

The distinction matters whenever a headline mentions billions of dollars or a claims deadline. Public-water-system settlements concern eligible water providers and specified contamination and testing circumstances. A firefighter alleging a disease is pursuing a different type of claim with different proof. A property owner, airport or sovereign entity may present still another theory. Using a water-provider settlement amount to predict an individual's recovery is not a defensible comparison.

Where the personal-injury bellwether process stands

The court built an initial personal-injury program through the CMO 26 series. In May 2024 it described a pool of 25 plaintiffs from two contamination sites asserting kidney cancer, testicular cancer, thyroid disease and ulcerative colitis. Later orders added claim-vetting and census work. In August 2025, CMO 35 vacated the October 20, 2025 trial date because the court needed a clearer picture of a large filed and unfiled inventory.

The process did not disappear. CMO 26.N, filed March 17, 2026, selected additional Group B plaintiffs to advance and directed the parties to submit expert-discovery proposals by July 20, 2026. That is the most useful public status marker reviewed here. It describes case selection and expert work, not a merits ruling and not a personal-injury settlement schedule. The selected cases are samples for litigation management; they do not pre-approve the same diseases in every claimant.

What government health sources say about PFAS

PFAS are a large family, not one chemical. EPA identifies firefighting foam as one possible exposure source and notes that PFOA and PFOS are among the most studied compounds. ATSDR says epidemiological evidence suggests associations between increased exposure to particular PFAS and several outcomes, including higher cholesterol, lower antibody response to some vaccines, changes in liver enzymes, pregnancy-induced hypertension, small decreases in birth weight, and kidney and testicular cancer for PFOA.

Those statements require their qualifiers. ATSDR says risk depends on dose, frequency, route, duration, individual susceptibility and other health determinants; it also notes inconsistent human findings and limitations in study design. An association observed across a population does not diagnose a person or prove where that person's exposure came from. The MDL's expert process exists precisely because general causation, exposure reconstruction and individual medical causation are contested, technical questions.

Drinking-water regulation is relevant, but not a claim test

EPA's 2024 national drinking-water rule set enforceable maximum contaminant levels for PFOA and PFOS at 4 parts per trillion and addressed four additional PFAS individually or through a hazard index. The regulation is a public-health control for covered water systems. It is important context for contamination and remediation, but crossing a regulatory threshold does not automatically prove tort causation, identify a foam manufacturer or establish damages.

Exposure reconstruction may draw on employment records, training logs, military or airport assignments, foam-product records, water sampling, addresses, blood testing and medical history. Each source answers a different question. Serum testing can show measured compounds at one point in time; it generally cannot by itself identify the product or defendant responsible, establish a historic dose, or determine what caused a disease. Clinical interpretation should come from qualified health professionals.

How to read claims and settlement updates safely

First identify the claimant category. Then verify the statement on the court's MDL page, the relevant order, an official administrator site or the actual agreement. Look for exact definitions, exclusions, release language and dates. Do not assume that terms for Phase One public-water systems apply to later systems, property claims or personal injury. Even within one category, objections, appeals, allocation procedures and documentation can affect timing.

For personal-injury updates, focus on the CMO 26 sequence, expert rulings, trial scheduling and case-specific orders. The monthly JPML number is useful for scale but not for valuation. As of July 10, 2026, the reviewed public materials do not supply a universal AFFF personal-injury payout table. Any site claiming guaranteed qualification based only on occupation and diagnosis is skipping product, exposure, medical and jurisdictional questions that remain central.

Reader questions

Frequently asked questions